• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Katie Pfaff

Katie Pfaff

katie.pfaff@clarivate.com
Articles

ARTICLES

Orthofix receives FDA nod for Charcot foot beaming system

March 23, 2018
By Katie Pfaff
Orthofix International NV won FDA 510(k) clearance for its internal fixation system G-beam Fusion for patients with Charcot foot. The beaming system can align, fixate and stabilize the foot by implanting beams in the lateral and medial foot columns. Charcot foot often is associated with unmanaged diabetes and can lead to nerve damage, deteriorated foot bones and eventual breakdown of the foot.
Read More

BSX buys BPH device maker for $306M in cash, plus milestones and minority stake investment

March 22, 2018
By Katie Pfaff
Boston Scientific Corp. has agreed to acquire private firm Nxthera Inc., a specialist in minimally invasive treatment of benign prostatic hyperplasia (BPH), for an upfront cash payment of $306 million, followed by as much as $100 million in possible milestone payments across the next four years. Boston Scientific is currently a minority investor in Nxthera and will make a $240 million net payment at closing, with milestones of as much as $85 million. The deal is expected to close in the second quarter of 2018.
Read More

Mardil marks first implantations with combo device for functional mitral valve regurgitation

March 21, 2018
By Katie Pfaff
Mardil Medical Inc. has completed a pair of first-in-human implants of its combination therapy Ventouch Triad device at Sanitorio Italiano in Asunción, Paraguay, among patients with type IIIb functional mitral valve regurgitation (FMR). The Ventouch Triad is designed to treat both the dilated ventricle and affected valve in FMR patients who often experience exacerbated heart failure without treatment.
Read More

Colibri Heart Valve begins enrollment for faster, easier 'dry tissue' TAVI device

March 20, 2018
By Katie Pfaff
Private company Colibri Heart Valve LLC reported the first two enrollees in the clinical early feasibility study of its second-generation expandable 24 mm and 27 mm transcatheter aortic valve (TAVI) system. The "package-to-patient" device has built on the earlier system that included a premounted, replacement aortic heart valve already precrimped to the balloon catheter, sheathed and sterilized so that it can be used directly from packaging. The newest device allows for adoption by additional patients, such as those with bicuspid aortic valves.
Read More

J&J offered $2.1B for Lifescan CGM business

March 19, 2018
By Katie Pfaff
Johnson & Johnson Corp.'s (J&J) Medical Devices group has received a binding offer of $2.1 billion for its Lifescan Inc. business, signaling further moves away from the diabetes sector after its 2017 closure of Animas. Blood glucose monitoring (BGM) company and maker of Onetouch devices, Lifescan, reported $1.5 billion in 2017 net revenue. Platinum Equity investment firm made the offer; the deal's acceptance period closes June 15. Should Johnson & Johnson accept, the transaction is anticipated to close by the end of the year. Lifescan offers BGM and insulin delivery devices.
Read More

Inivata and Medstar to collaborate in both liquid biopsy and ctDNA viability research

March 16, 2018
By Katie Pfaff
Cancer genomics firm Inivata Ltd. has launched a collaboration with Medstar and Medstar Georgetown Cancer Institute, bringing them into its Inivata Knowledge Accumulation Network (IKAN). IKAN has gathered together cancer centers around the world in an effort to evaluate circulating tumor DNA (ctDNA) and liquid biopsy capability using its Invision liquid biopsy platform. Medstar, Atrium Health's Levine Cancer Institute and the West Cancer Center are early joiners to IKAN.
Read More

New Tae unit launched to treat cancers gains $40M in financing and closes partnership deal

March 15, 2018
By Katie Pfaff
Tae Life Sciences, a majority-owned subsidiary of Tae Technologies Inc., launched this week, forging ahead in development of its investigational accelerator-based platform hoped to treat head, neck and glioblastoma multiforme (GBM) cancer. Tae Life Sciences has licensed IP from Tae Technologies for the accelerator-based neutron beam technology for Boron Neutron Capture Therapy (BNCT), and aims to expand treatment capabilities for these difficult-to-address malignancies. In conjunction with its launch, Tae Life Sciences also inked a partnership deal with Neuboron Medtech Ltd. and closed a $40 million venture round.
Read More

Apollo receives FDA OK to terminate Lap-band study based on existing data

March 14, 2018
By Katie Pfaff
Bariatric and gastrointestinal medical device firm Apollo Endosurgery Inc. has won FDA authorization to terminate its Lap-band lower BMI (LBMI) post-approval study due to long-term data on safety and effectiveness in already published evidence. LBMI's early termination will amount to about $5.1 million in savings for the company, expected over the length of the research. The study was anticipated to enroll as many as 325 patients at 20 sites; 181 patients had since the end of 2017 been enrolled at 13 clinical sites.
Read More

Laborie Medical looks to bolster its urology, endoscopy business with $239M Cogentix buy

March 13, 2018
By Katie Pfaff
Diagnostics, gastrointestinal and pelvic device company, Laborie Medical Technologies, has executed a definitive agreement to acquire Cogentix Medical Inc., developer of neurostimulation, endoscopy, and urology technology and devices. The deal was set at a cash purchase price of $3.85 per Cogentix share and enterprise value of $214 million. The share price is a 28 percent premium above the average closing price of Cogentix's common stock across the last 30 days. Under the deal, Laborie will acquire all outstanding shares of Cogentix for a total consideration of about $239 million.
Read More

Indidx liquid biopsy test may lead to reliable early lung cancer rule-out

March 12, 2018
By Katie Pfaff
Integrated Diagnostics Inc. (Indidx) has raised the bar on lung cancer detection with publication of study results regarding its Xpresys Lung 2 (XL2) liquid biopsy test for early stage disease. The differential diagnostic test has been confirmed to provide accurate distinction between benign and malignant nodules, possibly avoiding unnecessary biopsy or surgery in early suspect nodules. The study was published online Feb. 26, 2018, in CHEST, the journal of the American College of Chest Physicians.
Read More
View All Articles by Katie Pfaff

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 12, 2025.
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • Digital globe illustrating pharma trade, tariffs

    Navigating the Trump tariffs, part two: Amgen, Biogen, others

    BioWorld
    As biopharma companies continue to roll out their first-quarter  earnings, Trump administration tariffs remain at the top of investors’ minds. While executives...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 6, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe